Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo)

Vergnenègre, A.; Monnet, I.; Ricordel, Charles; Bizieux, A.; Curcio, H.; Bernardi, M.; Corre, Romain; Guisier, Florian; Hominal, S.; Garff, G. Le; Bylicki, Olivier; Locher, C.; Geier, M.; Chouaïd, C.; Robinet, G.

doi:10.1016/j.lungcan.2023.02.020

Cited by 5 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 30 Owing to the diverse antitumor mechanisms of metronomic chemotherapy, a growing number of studies are currently endeavoring to integrate metronomic chemotherapy with other interventions, including targeted therapy and immunotherapy, among others, for the purpose of treating tumors. 31 , 32 , 33 , 34 , 35 In recent years, metronomic chemotherapy has gained widespread application in a range of cancers, including BC, 36 , 37 esophageal and gastroesophageal cancer, 38 lung cancer, 39 pancreatic cancer, 40 ovarian cancer, 41 and others. The current regimen utilized the oral metronomic chemotherapy approach with a combination of drugs, with the advantages of convenient drug administration and higher pharmacoeconomic efficiency compared with intravenous administration.…”

Section: Discussionmentioning

confidence: 99%

A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer

et al. 2023

View full text Add to dashboard Cite

BackgroundThis single‐arm prospective phase II trial was performed to assess the efficacy and safety of the dual oral metronomic vinorelbine and capecitabine (mNC) regimen in women with HER2‐negative metastatic breast cancer (MBC) in China.MethodsThe mNC regimen was administered to the enrolled cases, including oral vinorelbine (VNR) 40 mg three times weekly (on days 1, 3 and 5 every week) and capecitabine (CAP) 500 mg three times a day, until disease progression or intolerable toxicity. The primary endpoint was the 1‐year progression‐free survival (PFS) rate. Secondary endpoints included objective response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR) and treatment‐related adverse events (TRAEs). Stratified factors included treatment lines and hormone receptor (HR) status.ResultsBetween June 2018 and March 2023, 29 patients were enrolled into the study. The median follow‐up time was 25.4 months (range, 2.0–53.8). In the entire group, the 1‐year PFS rate was 54.1%. ORR, DCR and CBR were 31.0%, 96.6% and 62.1%, respectively. The mPFS was 12.5 months (range, 1.1–28.1). Subgroup analysis revealed that ORRs were 29.4% and 33.3% in first‐ and ≥second‐line chemotherapy, respectively. ORRs were 29.2% (7/24) and 40.0% (2/5) for HR‐positive MBC and metastatic triple‐negative breast cancer (mTNBC), respectively. Grade 3/4 TRAEs were neutropenia (10.3%) and nausea/vomiting (6.9%).ConclusionsThe dual oral mNC regimen showed very good safety features and improved compliance without loss of efficacy in both first‐ and second‐line treatments. The regimen also reached an excellent ORR in the mTNBC subgroup.

show abstract

Section: Discussionmentioning

confidence: 99%

A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Moreover, a meta-analysis reported the significance of ICI addition to chemotherapy in increasing the risk of pneumonitis (OR 2.67, p < 0.00001) [48]. Interestingly, reduced grade 3 or 4 side effects were observed in metronomic vinorelbine and atezolizumab combinational therapy (13.3%) [49], compared to atezolizumab monotherapy (30.1%) [50], in NSCLC. The low-risk profile was also shown in the metronomic administration of capecitabine for sorafenib-resistant HCC [51].…”

Section: Combined Anti-cancer Treatmentsmentioning

confidence: 99%

Key Determinants of Immune-Mediated Adverse Reactions to Oncology Drugs

Zhou,

Ding

2023

Cancers

View full text Add to dashboard Cite

To overcome the epidemiological severity of cancer, developing effective treatments is urgently required. In response, immune checkpoint inhibitors (ICIs) have been revealed as a promising resolution for treatment-resistant cancers across the world. Yet, they have both advantages and disadvantages, bringing therapeutic benefits while simultaneously inducing toxicity, and in particular, immune-mediated adverse drug reactions (imADRs), to the human body. These imADRs can be pathogenic and sometimes lethal, hampering health prediction and monitoring following the provision of ICI treatment. Therefore, it is necessary to collectively identify the determinant factors that contribute to these imADRs induced by ICIs. This article evaluated treatment-, tumor-, and patient-related determinants, and indicated a research gap for future investigations on the pathogenic mechanism of imADRs and translational conversion of determinants into clinical biomarkers to aid pharmacovigilance and cancer therapies.

show abstract

Unveiling microtubule dynamics in lung cancer: Recent findings and prospects for drug delivery and treatment

Yukuyama,

de Souza,

Henostroza

et al. 2023

Journal of Drug Delivery Science and Technology

View full text Add to dashboard Cite

Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo)

Cited by 5 publications

References 26 publications

A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer

A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer

Key Determinants of Immune-Mediated Adverse Reactions to Oncology Drugs

Unveiling microtubule dynamics in lung cancer: Recent findings and prospects for drug delivery and treatment

Contact Info

Product

Resources

About